Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
BioGeneration Ventures (BGV) is a venture capital firm based in Naarden, Netherlands, focusing on early-stage funding for life sciences companies. As part of the Forbion-BGV platform, which includes Forbion Ventures and Forbion Growth, BGV manages over €100 million in funds. The firm primarily acts as a lead investor in seed rounds and supports Series A and B funding.
BGV invests in early-stage biotechnology companies, particularly those addressing high unmet medical needs. The firm collaborates with other investors and has established partnerships with academic institutions and healthcare companies across Europe and North America. Investment sizes typically range from seed funding to support for Series A and B rounds.
Notable portfolio companies include Acerta Pharma, co-founded by BGV, which developed the FDA-approved drug Calquence® and was sold to AstraZeneca for up to $7 billion in 2016. Other companies include Catalym, Epsilogen, Genase Therapeutics, and NorthSea Therapeutics, each focusing on innovative therapeutic solutions.
Submit your pitch through their form at biogenerationventures.com or email info@biogeneration.vc with your deck.
Yes, BGV primarily acts as a lead investor in seed funding rounds for biotechnology companies.
BGV supports follow-on investments, particularly in Series A and B rounds, to help portfolio companies scale.
BGV manages over €100 million in funds, allowing for significant investments in early-stage life sciences companies.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.